Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

* Participants must have met all of the following criteria to be included in this study: 1. Diagnosis of epilepsy 2. Initiated treatment with Fycompa at any time after 01 Jan 2014 3. Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records (if required by an Institutional Review Board \[IRB\] or Independent Ethics Committee \[IEC\], or by regulatory authorities).

Exclusion criteria

* Not applicable

Design outcomes

Primary

Measure	Time frame	Description
Percentage of participants remaining on Fycompa treatment at specified time points after initiation of treatment (Retention rate)	3, 6, 12, 18, and 24 months	Retention rate is the ratio of the number of participants remaining on Fycompa treatment to the number of participants who could have been exposed for that length of time.

Secondary

Measure	Time frame	Description
Number of participants with a 75% response rate	up to 24 months	The response rate will be evaluated from seizure frequencies recorded in medical records or seizure diaries, where available. If not available, the investigator assessment of the therapeutic response will be used.
Number of participants with a 100% response rate	up to 24 months	The response rate will be evaluated from seizure frequencies recorded in medical records or seizure diaries, where available. If not available, the investigator assessment of the therapeutic response will be used.
Categorized percent reduction in seizure frequency from baseline	Baseline, up to 24 months	An epileptic seizure or seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a momentary loss of awareness (absence seizure).
Median percent change in seizure frequency from baseline	Baseline, up to 24 months	An epileptic seizure or seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a momentary loss of awareness (absence seizure).
Percentage of participants who had no change or a worsening of seizures from baseline	Baseline, up to 24 months	An epileptic seizure or seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a momentary loss of awareness (absence seizure).
Total provider health care visits before, during, and after final dose of Fycompa	6 months before initiation of Fycompa to 6 months after last dose of Fycompa	Total provider health care visits before, during, and after final dose of Fycompa will be summarized as a safety variable.
Number of participants with a 50% response rate	up to 24 months	The response rate will be evaluated from seizure frequencies recorded in medical records or seizure diaries, where available. If not available, the investigator assessment of the therapeutic response will be used.
Number of participants with any treatment-emergent adverse event (TEAE) resulting in discontinuation of Fycompa	Up to 24 months	An AE is any untoward medical occurrence in a participant or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product. A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.
Mean change in body weight from baseline	Baseline, Up to 24 months	Change from baseline is calculated as the post-baseline value minus the baseline value.
Mean change in height of pediatric participants from baseline	Baseline, Up to 24 months	Change from baseline is calculated as the post-baseline value minus the baseline value.
Maximum dose of Fycompa	Up to 24 months	The extent of exposure of Fycompa will be determined by summarizing the maximum dose of the study drug.
Average dose of Fycompa	Up to 24 months	The extent of exposure of Fycompa will be determined by summarizing the average dose of the study drug.
Number of participants with any treatment-emergent (TE) serious adverse event (SAE) resulting in discontinuation of Fycompa	Up to 24 months	An SAE is any untoward medical occurrence that at any dose: results in death; is life threatening (ie, the participant was at immediate risk of death from the adverse events \[AE\] as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.

Countries

United States

Outcome results

None listed

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design